Health startups and the health economy: count the change, not the round

The UK has thousands of small health and life sciences companies and a health service that says it needs them. Their real effect on the health economy depends on whether anything changes for patients and services, not on how much they raise.

24 October 2026 · 6 min read
6,500Businesses operating in UK life sciences, 2024/25, employing 306,700 people (Office for Life Sciences)
88%Share of UK life sciences companies that are SMEs, 2024/25 (Office for Life Sciences)
33%MedTech firms reporting they had removed products from the UK market in 2024 (Life Sciences Sector Plan, July 2025)
5.8%Healthcare productivity in 2025 below its 2019 pre-pandemic level (ONS)

The UK has a large health innovation sector, and most of it is small. The Office for Life Sciences counts 6,500 businesses operating in UK life sciences in 2024/25, across 7,600 companies. Together they employed 306,700 people and generated £125.8 billion of turnover. Medical technology accounts for 59% of the companies and 52% of the jobs. Small and medium-sized enterprises make up 88% of all companies.

The direction is less encouraging. Employment fell 2% on the year and turnover 1%. The statistics are labelled as in development and the method changed in 2023/24, so long-run comparisons need care, but the latest year was not one of growth.

Money is tighter

Investment has cooled too. HSBC Innovation Banking’s venture financing report for 2025 says the UK healthtech market shrank 17% year on year. The BioIndustry Association reported £1.79 billion of venture capital for UK biotech in 2025 across 58 deals, down 13.2%. Biotech and healthtech are different markets, but they point the same way. Fewer rounds mean founders have to show value sooner, and to buyers who are under pressure themselves.

The system says it needs them

The NHS has rarely been clearer that it needs new technology. Lord Darzi’s independent investigation of the NHS in England, published in September 2024, described the service as being in the foothills of digital transformation, called for a major tilt towards technology to unlock productivity, and identified a shortfall of £37 billion in capital investment. The 10 Year Health Plan, published in July 2025, describes the NHS as a technological laggard and commits to expanding NICE’s technology appraisal process to cover devices, diagnostics and digital products.

The need shows in the productivity figures. The ONS estimates that healthcare productivity rose 1.1% in 2024 and 1.0% in 2025, but was still 5.8% below its 2019 level.

But adoption is slow and uneven

The government’s Life Sciences Sector Plan, published in July 2025, is candid about the problem. It says uptake of medicines and medical technologies is seen as highly variable across the NHS, and describes routes to procurement as complicated and locally variable. It reports that in 2024, 33% of MedTech firms said they had removed products from the UK market. It commits to an NHS Innovator Passport for medtech by 2026.

NICE estimates there are around 2 million healthtech products available in the UK, with multiple routes into the NHS. No buyer can assess that many. In practice, a trust or integrated care board will look closely at a handful, and choose the ones that make the clearest case.

The lag between a good idea and normal practice is long. A review in the Journal of the Royal Society of Medicine in 2011 examined the often-quoted claim that research takes an average of 17 years to reach clinical practice. The authors traced the figure back to a small number of estimates and warned that the average hides a great deal of variation. The precise number is less important than the point: useful innovation usually takes years to become standard care.

What the support programmes count

England’s health innovation networks exist to close that gap. For 2025/26 they report almost £1.5 billion of investment leveraged, more than 1,500 jobs created or safeguarded, more than 2,300 innovators supported and more than 2.1 million patients benefiting. The NHS Innovation Accelerator reports that since 2015 its innovations have been adopted by 3,532 NHS organisations and reached 13.1 million patients, with 1,345 jobs and over £246 million of external investment.

These are real figures, and they show real activity. But they are reported by the programmes themselves, and most of them measure the health of the companies: money raised, jobs, organisations signed up. The patient counts are the closest thing to an outcome, and they tell you how many people a product reached, not what changed for them.

What this means: the health economy is not the same as the startup economy. A company can raise money, hire, and sell into dozens of trusts without improving anyone’s health. Its value to the system comes later and further down the line: fewer admissions, quicker recovery, people back at work, staff time released for other patients.

What a startup should be measured on

For founders, the practical point is that the evidence a buyer needs and the evidence of real impact are the same thing. Say what outcome you change and for whom. Measure it before and after, in the setting where you will actually be used, not only in a pilot built around you. Express what it saves in terms a finance director recognises, such as bed days, appointments or staff hours. And show who it reaches: the people with the worst health, or only the ones who were easiest to serve.

For commissioners and investors, the same test applies from the other side. Ask for outcomes before activity. Treat funding raised and contracts signed as signs of momentum, not proof of value.

Startups add to the health economy in two ways. One is direct: jobs, investment and turnover, which the sector statistics capture well. The other runs through the health service: care that works better and people who are healthier as a result. The second is larger, harder to count and the one that justifies the public money and clinical time that adoption takes. The question we would put to any health startup, and to ourselves, is the same one: whose life changed, and how do you know?

Newsletter

Practical ideas, once a month.

Website, growth and marketing tips for small and growing businesses. No spam, and you can unsubscribe at any time.